You can buy or sell IDXG and other stocks, options, ETFs, and crypto commission-free!
Interpace Diagnostics Group, Inc. operates as an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. Read More The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.
Parsippany, New Jersey
52 Week High
52 Week Low
Stock Price, News, & Analysis for Interpace Diagnostics Group
News stories about IDXG stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Interpace Diagnostics Group earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned press coverage about t...
Simply Wall StFeb 28
Those Who Purchased Interpace Diagnostics Group Shares Five Years Ago Have A 98% Loss To Show For It
Long term investing works well, but it doesn’t always work for each individual stock. We don’t wish catastrophic capital loss on anyone. Spare a thought for those who held Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) for five whole years – as the share price tanked 98%. There was little comfort for shareholders in the last week as the price declined a further 2.9%. We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don’t have to lose the les...
-$0.08 per share
-$0.09 per share